Adaptiiv Medical Technologies

SoftwareHalifax, CanadaFounded 2016· One of 367 Software companies tracked by AMPulse

A regulatory-cleared software platform that enables the design and 3D printing of patient-specific medical devices and accessories for radiation oncology.

CEO / Founder: Alex Dunphy
Team Size: 11-50
Stage: Active
Total Funding: $10.5M
Latest Round: Series A
Key Investors: Build Ventures, Nova Scotia Business Inc. (NSBI), Atlantic Canada Opportunities Agency (ACOA), Concrete Ventures

Technology & Products

Key Products

A regulatory-cleared software platform that enables the design and 3D printing of patient-specific medical devices and accessories for radiation oncology.

Technological Advantage

Seamlessly integrates with existing clinical workflows by converting DICOM RT data directly into 3D-printable files, reducing manual labor and eliminating the inaccuracies of traditional wax or plastic boluses.

Differentiation

Value Proposition

Improves clinical precision and patient comfort by replacing generic, hand-made radiotherapy accessories with 3D-printed devices that conform perfectly to a patient’s unique anatomy, ensuring accurate dose delivery while sparing healthy tissue.

How They Differentiate

Adaptiiv differentiates through a software-first, vendor-neutral approach that integrates directly with existing Treatment Planning Systems (TPS). Unlike competitors that focus on centralized manufacturing (like .decimal), Adaptiiv enables clinics to design and 3D print patient-specific devices locally, reducing turnaround time from weeks to hours.

Market & Competition

Target Customers

Radiation oncology clinics, hospitals, medical physicists, and radiation therapists at cancer treatment centers.

Industry Verticals

Healthcare, Medical Devices, Radiation Oncology, Additive Manufacturing (3D Printing)

Competitors

.decimal (Dot Decimal); 3D Systems (Healthcare Division); Stratasys (Medical Solutions)

Growth & Milestones

Growth Metrics

Expanded clinical footprint to over 20 countries; Gold Tier Alliance Member in Varian’s 3cosystem.

Major Milestones

Received first FDA 510(k) clearance for 3D Bolus software in 2018, Established strategic partnership with HP for Multi Jet Fusion integration in 2020, Secured $5M Series A funding led by Build Ventures in 2021, Achieved CE Mark and TGA approvals for international expansion, Partnered with Varian (Siemens Healthineers) for global distribution

Notable Customers

Mayo Clinic; MD Anderson Cancer Center; Nova Scotia Health; BC Cancer - Kelowna

https://www.adaptiiv.com

Why this company matters

AMPulse analysis, not a company disclosure

Adaptiiv Medical Technologies occupies a narrow but critical niche in radiation oncology: software that converts DICOM RT data from treatment planning systems into 3D-printable files for patient-specific boluses and other accessories. The platform received FDA 510(k) clearance in 2018, making it the first software cleared specifically for 3D printing radiotherapy accessories. By enabling local, on-demand production, it reduces turnaround time from weeks to hours compared to centralized manufacturing models.

The core technology integrates directly with existing clinical workflows, eliminating manual steps and the inaccuracies of traditional wax or plastic boluses. Clinics use polymer AM processes such as HP's Multi Jet Fusion to produce devices that conform precisely to a patient's anatomy, improving dose delivery accuracy and sparing healthy tissue. The platform is vendor-neutral, allowing facilities to choose their own 3D printing hardware.

Adaptiiv's target customers are radiation oncology clinics, hospitals, medical physicists, and therapists at cancer treatment centers. Notable users include Mayo Clinic, MD Anderson Cancer Center, Nova Scotia Health, and BC Cancer. The company has expanded to over 20 countries and holds Gold Tier Alliance membership in Varian's 3cosystem, a distribution channel through Siemens Healthineers. Key hardware partners include HP for MJF integration and Varian for global distribution.

The company's software-first approach differentiates it from competitors like .decimal, which focuses on centralized manufacturing, and from 3D Systems and Stratasys, which emphasize hardware. Adaptiiv's strategic moat lies in its regulatory clearances (FDA, CE Mark, TGA) and its integration with treatment planning systems. An open question is whether local production can achieve the consistency and quality control that centralized services provide, particularly as clinics scale personalized workflows.